Previous 10 | Next 10 |
PITTSBURGH, May 02, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepte...
NeuBase Therapeutics press release ( NASDAQ: NBSE ): Q1 GAAP EPS of -$0.13 misses by $0.02 . As of December 31, 2022, the Company had cash and cash equivalents of approximately $17.4 million, compared with approximately $23.2 million as of September 30, 2022. NeuBase estim...
PITTSBURGH, Feb. 14, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, tod...
Penny Stocks Under $1 To Watch This Week unless you’ve been living under a rock, you know how bearish the stock market is right now. Since the beginning of the year, major indexes are trading lower. While some are dipping more than others, market participants are finding different ways...
NeuBase Therapeutics press release ( NASDAQ: NBSE ): FY GAAP EPS of -$1.04 beats by $0.04 . As of September 30, 2022, the Company had cash and cash equivalents of approximately $23.2 million, compared with approximately $52.9 million as of September 30, 2021. Shares +5% ...
PITTSBURGH, Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, tod...
NeuBase Therapeutics ( NASDAQ: NBSE ) on Friday said it signed a gene editing research agreement with one of the top 10 global healthcare companies. The healthcare company will evaluate NeuBase's PATrOL technology for three monogenic genetic diseases. PATrOL is a pepti...
PITTSBURGH, Oct. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicine...
NeuBase Therapeutics ( NASDAQ: NBSE ) on Friday announced a strategic restructuring to focus on its gene editing platform, including ~60% job cuts and a cost reduction plan that will extend its cash runway into Q2 CY24. Shares of NBSE, which ended 9.7% lower on ...
Workforce reductions of ~60% and implementation of a robust cost reduction plan are expected to extend the Company’s cash runway into Q2 CY2024 The Company plans to maximize shareholder value by focusing R&D resources on advancement of the differentiated gene editing ...
News, Short Squeeze, Breakout and More Instantly...
NeuBase Therapeutics Inc. Company Name:
NBSE Stock Symbol:
NYSE Market:
NeuBase Therapeutics Inc. Website:
Usinas Siderurgicas De Minas Gerais S.A. ADR (Representing Pref Share Cl A) (USNZY) is expected to report $0 for Q2 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Senstar Technologie...
Verbund AG ADR (OEZVY) is expected to report for Q1 2024 Rent the Runway Inc. (RENT) is expected to report $-6.56 for Q1 2025 Johnson Matthey plc ADR (JMPLY) is expected to report for Q4 2024 RVL Pharmaceuticals plc (RVLPQ) is expected to report for Q1 2024 Ciena Corporation (CIEN...
Macquarie Group Ltd ADR (MQBKY) is expected to report for Q4 2024 Hormel Foods Corporation (HRL) is expected to report $0.35 for Q2 2024 Howden Joinery Group Plc ADR (HWDJY) is expected to report for Q1 2024 Eiger BioPharmaceuticals Inc. (EIGRQ) is expected to report for Q1 2024 M...